V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160013354 | 160006493 | 1.59 | 60 | Palliative (P) | 2016-06-05 | 2016-06-09 | IVADo | 02 | N | CARBOPLATIN + PACLITAXEL | 101067696 |
| 160013355 | 160006494 | 1.8 | 87.6 | Palliative (P) | 2018-04-18 | 2018-04-30 | DOXORUBICIN | 02 | 2 | ETOP 13-18 BEAT-MESO TRIAL | 100691443 |
| 160013357 | 160006495 | 1.66 | 70 | Curative (C) | 2018-03-14 | 2018-03-21 | Trial Unspecified | 02 | N | NOT MATCHED | 101067983 |
| 160013359 | 160006496 | 1.88 | 72.4 | null | 2020-07-09 | 2020-07-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101005052 |
| 160013360 | 160006497 | null | null | Palliative (P) | null | 2020-07-11 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100280894 |
| 160013364 | 160006498 | 1.54 | 55.7 | Palliative (P) | 2018-02-18 | 2018-02-19 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 101684272 |
| 160013365 | 160006499 | 1.72 | 90 | Palliative (P) | 2016-12-11 | 2017-01-02 | Trial Unspecified | N | N | DOXORUBICIN + IFOSFAMIDE | 100523332 |
| 160013368 | 160006500 | 1.68 | 83 | Neo-adjuvant (N) | 2020-01-21 | 2020-01-21 | ICON8B TRIAL | 02 | N | LIPOSOMAL DOXORUBICIN | 100531601 |
| 160013370 | 160006501 | 1.67 | 83 | Palliative (P) | null | 2020-09-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101253854 |
| 160013371 | 160006502 | 1.7 | 89 | Palliative (P) | 2019-06-05 | 2019-06-05 | Abiraterone | N | null | PEMETREXED | 101050318 |
| 160013372 | 160006503 | 1.8 | 80 | null | 2020-07-25 | 2020-08-03 | Vinorelbine (oral) | 02 | N | NOT MATCHED | 101726089 |
| 160013373 | 160006504 | 1.63 | 72.4 | Curative (C) | 2022-03-14 | 2022-03-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101561088 |
| 160013374 | 160006505 | 1.68 | 156 | Palliative (P) | null | 2016-03-04 | Pemetrexed | 02 | N | DACTINOMYCIN + VINCRISTINE | 100159492 |
| 160013375 | 160006506 | 1.73 | 88.9 | Palliative (P) | 2017-06-01 | 2017-06-18 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101181422 |
| 160013378 | 160006507 | 1.78 | 92.1 | Palliative (P) | null | null | EW EuroEwing 2012 Arm B VDC | 02 | N | EW EUROEWING 2012 ARM A VIDE | 100416606 |
| 160013379 | 160006508 | 1.87 | 75.8 | Neo-adjuvant (N) | 2017-11-08 | 2017-11-24 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100401618 |
| 160013380 | 160006509 | 0 | 0 | Curative (C) | 2016-10-03 | 2016-10-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101412917 |
| 160013381 | 160006510 | 1.66 | 87.7 | Palliative (P) | 2018-10-15 | 2018-10-22 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | DOXORUBICIN | 101201492 |
| 160013382 | 160006511 | 1.93 | 119 | Palliative (P) | 2017-09-06 | 2017-09-26 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100623492 |
| 160013383 | 160006512 | 0 | 35.1 | Palliative (P) | 2020-03-28 | 2020-04-04 | EW EuroEwing 2012 Arm B VDC | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100248195 |
| 160013384 | 160006513 | 1.83 | 78.6 | Palliative (P) | 2018-04-10 | 2018-04-25 | VINORELBINE | null | N | CISPLATIN + DOXORUBICIN | 100590311 |
| 160013385 | 160006514 | 1.76 | 67.5 | Curative (C) | 2018-11-29 | 2019-01-04 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101523717 |
| 160013389 | 160006515 | 1.66 | 95.6 | 03 | 2016-08-28 | 2016-08-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101833545 |
| 160013391 | 160006516 | 1.64 | 109.8 | Palliative (P) | 2017-04-17 | 2017-04-27 | STS Rhabdomyosarcoma RMS 2005 IVA | 01 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100657827 |
| 160013393 | 160006517 | 1.78 | 86 | Neo-adjuvant (N) | 2018-12-13 | 2018-12-20 | Doxorubicin + Olaratumab | 02 | N | EW EUROEWING 2012 ARM B VDC | 101436262 |
| 160013394 | 160006518 | 1.66 | 64.5 | null | 2017-09-06 | 2017-09-06 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100193155 |
| 160013397 | 160006519 | 1.85 | 54.5 | null | 2017-01-17 | 2017-01-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101442422 |
| 160013398 | 160006520 | 1.73 | 93.1 | Palliative (P) | 2016-06-17 | 2016-06-27 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 100551492 |
| 160013402 | 160006521 | 1.82 | 94 | Neo-adjuvant (N) | 2016-09-07 | 2016-09-08 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101472333 |
| 160013403 | 160006522 | null | null | null | 2019-02-24 | 2019-02-24 | Cisplatin + Paclitaxel | N | null | LIPOSOMAL DOXORUBICIN | 101628982 |
| 160013407 | 160006523 | 1.9 | 54 | 03 | 2017-06-23 | 2017-07-01 | Trial Unspecified | N | null | LIPOSOMAL DOXORUBICIN | 101212077 |
| 160013408 | 160006524 | 1.51 | 81.3 | Palliative (P) | 2018-03-05 | 2018-03-30 | Ifosfamide | 02 | N | LIPOSOMAL DOXORUBICIN | 101393182 |
| 160013409 | 160006525 | 1.66 | 80 | Neo-adjuvant (N) | 2017-11-18 | 2017-11-18 | GC Int Guide Excranial GermCell JEB | 02 | N | CISPLATIN + PACLITAXEL | 100716809 |
| 160013411 | 160006526 | 1.73 | 83 | Neo-adjuvant (N) | 2019-10-26 | 2019-11-03 | null | 02 | N | CISPLATIN + PEMETREXED | 101717828 |
| 160013414 | 160006527 | 1.63 | 66.8 | null | 2017-12-07 | 2017-12-20 | Liposomal Doxorubicin (20mg/m2) | 02 | N | CISPLATIN + PACLITAXEL | 100000701 |
| 160013415 | 160006528 | 1.74 | 63.8 | 03 | 2019-08-02 | 2019-08-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101401710 |
| 160013416 | 160006529 | 1.67 | 78.4 | Palliative (P) | 2018-12-25 | 2019-01-02 | STS Non-Rhabdo EpSSG 2005 VDCy | 02 | N | NB HRNBL-1 COJEC IND COURSE A | 101195834 |
| 160013419 | 160006530 | null | null | Curative (C) | null | 2021-03-08 | Cisplatin + Pemetrexed | null | null | CISPLATIN + PEMETREXED | 100153287 |
| 160013420 | 160006531 | 1.78 | 87.1 | 03 | 2017-05-04 | 2017-05-04 | Bevacizumab 7.5mg/kg | 02 | N | DOXORUBICIN + OLARATUMAB | 100363637 |
| 160013425 | 160006533 | 0 | 19.5 | Palliative (P) | 2017-05-21 | 2017-05-22 | Trial Unspecified | 02 | null | ENZALUTAMIDE | 101864037 |
| 160013426 | 160006534 | 1.76 | 70 | Neo-adjuvant (N) | 2017-12-13 | 2017-12-18 | Trial Unspecified | 02 | N | LIPOSOMAL DOXORUBICIN | 101235870 |
| 160013427 | 160006535 | 1.82 | 78.3 | Curative (C) | 2017-11-10 | 2017-11-11 | ICON8B TRIAL | 01 | N | EW EUROEWING 2012 ARM B VDC | 100153219 |
| 160013430 | 160006536 | null | null | Curative (C) | 2017-12-01 | 2017-12-06 | PACLITAXEL | 01 | null | LIPOSOMAL DOXORUBICIN | 101105794 |
| 160013433 | 160006537 | 1.2 | 73.2 | Palliative (P) | 2018-06-27 | 2018-07-01 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100346681 |
| 160013434 | 160006538 | 1.74 | 90.4 | null | 2019-11-25 | 2019-11-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100418340 |
| 160013440 | 160006539 | 1.88 | 57 | Curative (C) | 2017-12-28 | 2018-01-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101808874 |
| 160013444 | 160006540 | 1.55 | 84 | Palliative (P) | 2019-11-13 | 2019-11-17 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | DOXORUBICIN | 101333690 |
| 160013448 | 160006541 | 1.67 | 79.5 | null | 2017-04-14 | 2017-04-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101190815 |
| 160013452 | 160006542 | 1.82 | 66.4 | Palliative (P) | 2018-03-15 | 2018-04-06 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100000507 |
| 160013453 | 160006543 | 1.86 | 62.4 | Palliative (P) | 2018-12-23 | 2018-12-30 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 100513473 |